Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience
Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterised by t(15;17) and PML/RAR alfa fusion gene. The invention of the molecular pathogenesis has led to entitle all-trans retinoic acid (ATRA) as the primary focused remedy for acute leukemia. It’s often related to anthracycline-based chemotherapy with excessive response charges, however potential long-term sequelae together with therapy-related malignancies have been noticed.
Arsenic trioxide (ATO) was added to obviate these issues and investigational trials aimed to a brand new technique with the incorporation of arsenic trioxide (ATO) into preliminary remedy as an alternative of chemotherapy in chosen sufferers. ATRA plus ATO with out chemotherapy was the primary try to deal with low and intermediate-risk sufferers with APL. Our examine goals to explain a monocentric cohort of sufferers with newly recognized APL successfully handled with ATO plus ATRA underlying its efficacy along with the excessive grade of tolerability of this affiliation.
From January 2009 to December 2019 23 APL sufferers have been recognized and handled with ATO plus ATRA routine: 14 males and 9 females sufferers with a median age of 45 years (vary 18-72), for almost all intermediate threat (15 sufferers, 65%). The remedy was properly tolerated and all sufferers achieved molecular remission after a median time of three months (vary 1-6 months). All sufferers proceeded to consolidation section as outpatients, they maintained full molecular response at a median time of 44 months (vary 15-127) apart from 1 affected person.
All however one affected person are alive and in response at a median follow-up of 48 months (vary 9-141) with out late results. ATO plus ATRA routine exhibits benefits compared to chemotherapy; actually it allowed to deal with sufferers during which chemotherapy may even not be relevant and it didn’t present secondary hematological ailments. The affiliation of ATO to ATRA as chemo-free routine enabled to deal with APL even with out chemotherapy.
Investigation of the ameliorative results of baicalin in opposition to arsenic trioxide-induced cardiac toxicity in mice
Baicalin (BA), a form of flavonoids compound, comes from Scutellaria baicalensis Georgi (a form of perennial herb) and has useful results on the cardiovascular system by means of anti-oxidant, anti-inflammation, and anti-apoptosis actions. Nevertheless, the therapeutic results and latent mechanisms of BA on arsenic trioxide (ATO)-induced cardiac toxicity has not been reported. The current analysis was carried out to discover the results and mechanisms of BA on ATO-induced coronary heart toxicity.
Male Kunming mice have been handled with ATO (7.5 mg/kg) to induce cardiac toxicity. After the mice obtained ATO, BA (50 and 100 mg/kg) was administered for estimating its cardioprotective results. Statistical information demonstrated that BA remedy alleviated electrocardiogram abnormalities and pathological harm attributable to ATO.
BA may additionally result in restoration of CK and LDH actions to regular vary and trigger a lower in MDA ranges and ROS technology, augmentation of SOD, CAT, and GSH actions. We additionally discovered that BA prompted a discount within the expression of proinflammatory cytokines, akin to TNF-α and IL-6. Furthermore, BA attenuated ATO-induced apoptosis by selling the expression of Bcl-2 and suppressing the expression of Bax and caspase-3. TUNEL take a look at consequence demonstrated BA prompted obstacle of ATO-induced apoptosis.
Moreover, BA remedy suppressed the excessive expression of TLR4, NF-κB and P-NF-κB attributable to ATO. In conclusion, these outcomes point out that BA might alleviate ATO-induced cardiac toxicity by restraining oxidative stress, apoptosis, and irritation, and its mechanism can be related to the inhibition of the TLR4/NF-κB signaling pathway.
Comparative Analysis of Mineral Trioxide Mixture Obturation Utilizing 4 Totally different Methods-A Laboratory Research
This examine aimed to check the density of mineral trioxide combination (MTA) as a root canal filling materials within the apical 5 mm of synthetic root canals. Forty clear acrylic blocks with 30-degree curved canals have been instrumented and allotted into 4 compaction method teams (n = 10): Lawaty (hand recordsdata); gutta-percha (GP) factors; auger (nickel-titanium rotary recordsdata in reverse mode); and plugger method. Crammed canals have been weighed after setting the MTA to calculate distinction in mass.
Two postoperative radiographs in contrast radiopacity by measuring luminance variations at 0.5 mm, 1 mm, 2 mm, Three mm, four mm, and 5 mm from the basis apex. Obturation time was measured utilizing a digital chronometer. The importance stage was set to p < 0.05. The plugger group had a decrease mass. Relative luminance was considerably greater for the Lawaty group than the plugger group in any respect examined apical ranges.
The relative luminance of the auger and GP teams have been considerably greater than the plugger group at depths between 0.5 mm and a couple of mm. Relative luminance was highest for the Lawaty method in any respect depths between 0.5 mm and four mm. The Lawaty method group was related to elevated obturation time in contrast with pluggers. Compacting MTA in curved canals with the Lawaty method has the best mass and radiopacity however requires extra time.
Arsenic trioxide encapsulated liposomes prepared via copper acetate gradient loading method and its antitumor efficiency
In this study, arsenic trioxide (ATO) was encapsulated in liposomes via copper acetate (Cu(OAc)2) gradients and high entrapment efficiency of over 80% was obtained. The average particle size and the zeta-potential of the liposomes were detected to be 115.1 ± 29.1 nm and -21.97 ± 0.6 mV, respectively.
The TEM images showed rod-like precipitates in the inner aqueous phase, which was supposed be due to the formation of insoluble ATO-Cu complex. The in vitro drug release of ATO-Cu liposomes exhibited a sustained release over 72 h, and the release rates decreased with the increase of the pH of release media. Pharmacokinetic and tissue distribution studies of ATO liposomes showed significantly reduced plasma clearance rate, increased AUC0-12 h and T1/2, and improved tumor distribution of As compared to iv administration of ATO solution.
The anti-tumor effect of ATO loaded liposomes to S180 tumor-bearing mice was significantly improved with a tumor inhibition rate of 61.2%, meanwhile the toxicity of encapsulated ATO was greatly decreased.
Mouse Androgen Receptor (AR) ELISA Kit |
|||
| DLR-AR-Mu-48T | DL Develop | 48T | EUR 508 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Androgen Receptor (AR) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Mouse Androgen Receptor (AR) ELISA Kit |
|||
| DLR-AR-Mu-96T | DL Develop | 96T | EUR 661 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Androgen Receptor (AR) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Rat Androgen Receptor (AR) ELISA Kit |
|||
| DLR-AR-Ra-48T | DL Develop | 48T | EUR 528 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Androgen Receptor (AR) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Rat Androgen Receptor (AR) ELISA Kit |
|||
| DLR-AR-Ra-96T | DL Develop | 96T | EUR 690 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Androgen Receptor (AR) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Human Androgen Receptor (AR) ELISA Kit |
|||
| RDR-AR-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 522 |
Human Androgen Receptor (AR) ELISA Kit |
|||
| RDR-AR-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 724 |
Mouse Androgen Receptor (AR) ELISA Kit |
|||
| RDR-AR-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 534 |
Mouse Androgen Receptor (AR) ELISA Kit |
|||
| RDR-AR-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 742 |
Rat Androgen Receptor (AR) ELISA Kit |
|||
| RDR-AR-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 558 |
Rat Androgen Receptor (AR) ELISA Kit |
|||
| RDR-AR-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 776 |
Molybdenum(VI) oxide, 99.9% |
|||
| GX8007-100G | Glentham Life Sciences | 100 g | EUR 130 |
Molybdenum(VI) oxide, 99.9% |
|||
| GX8007-1KG | Glentham Life Sciences | 1 kg | EUR 389 |
Molybdenum(VI) oxide, 99.9% |
|||
| GX8007-250G | Glentham Life Sciences | 250 g | EUR 183 |
Ar/ Rat Ar ELISA Kit |
|||
| ELI-04146r | Lifescience Market | 96 Tests | EUR 886 |
Molybdenum Cofactor Sulfurase (MOCOS) Antibody |
|||
| 20-abx113870 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 Protein |
|||
| 20-abx263321 | Abbexa |
|
|
Molybdenum Cofactor Sulfurase (MOCOS) Antibody |
|||
| abx235263-100ug | Abbexa | 100 ug | EUR 481 |
AR Antibody |
|||
| CSB-PA001975KA01HU- | Cusabio | EUR 335 | |
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100 |
|||
AR Antibody |
|||
| CSB-PA001975KA01HU-100ul | Cusabio | 100ul | EUR 389 |
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100 |
|||
AR Antibody |
|||
| 1-CSB-PA011255 | Cusabio |
|
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000 |
|||
AR Antibody |
|||
| 1-CSB-PA011256 | Cusabio |
|
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000 |
|||
AR Antibody |
|||
| 1-CSB-PA011257 | Cusabio |
|
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, IF, ELISA;IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/40000 |
|||
AR Antibody |
|||
| 1-CSB-PA011258 | Cusabio |
|
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
|||
AR Antibody |
|||
| 1-CSB-PA006094 | Cusabio |
|
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/10000 |
|||
AR Antibody |
|||
| 1-CSB-PA056943 | Cusabio |
|
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
|||
AR Antibody |
|||
| 1-CSB-PA05979A0Rb | Cusabio |
|
|
|
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
AR 231453 |
|||
| HY-15564 | MedChemExpress | 10mM/1mL | EUR 160 |
AR-A014418 |
|||
| HY-10512 | MedChemExpress | 50mg | EUR 342 |
AR-9281 |
|||
| HY-111151 | MedChemExpress | 5mg | EUR 211 |
AR-C155858 |
|||
| HY-13248 | MedChemExpress | 10mM/1mL | EUR 483 |
AR-08 |
|||
| HY-U00371 | MedChemExpress | 20mg | EUR 13439 |
AR Antibody |
|||
| 32572-100ul | SAB | 100ul | EUR 252 |
AR siRNA |
|||
| 20-abx908237 | Abbexa |
|
|
AR siRNA |
|||
| 20-abx908238 | Abbexa |
|
|
AR siRNA |
|||
| 20-abx900461 | Abbexa |
|
|
AR A014418 |
|||
| 20-abx076761 | Abbexa |
|
|
AR 231453 |
|||
| B3269-10 | ApexBio | 10 mg | EUR 245 |
|
Description: AR 231453 is an agonist of GPR119 with EC50 value of 0.68nM [1].AR 231453 is the first subnanomolar agonist of GPR119. It is highly selective against GPR119 over a 76 receptor and enzyme profiling panel (CEREP) including the known incretin receptors. |
|||
AR 231453 |
|||
| B3269-5 | ApexBio | 5 mg | EUR 179 |
|
Description: AR 231453 is an agonist of GPR119 with EC50 value of 0.68nM [1].AR 231453 is the first subnanomolar agonist of GPR119. It is highly selective against GPR119 over a 76 receptor and enzyme profiling panel (CEREP) including the known incretin receptors. |
|||
AR 231453 |
|||
| B3269-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 195 |
|
Description: AR 231453 is an agonist of GPR119 with EC50 value of 0.68nM [1].AR 231453 is the first subnanomolar agonist of GPR119. It is highly selective against GPR119 over a 76 receptor and enzyme profiling panel (CEREP) including the known incretin receptors. |
|||
AR-A014418 |
|||
| A3184-10 | ApexBio | 10 mg | EUR 128 |
|
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor. |
|||
AR-A014418 |
|||
| A3184-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 123 |
|
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor. |
|||
AR-A014418 |
|||
| A3184-50 | ApexBio | 50 mg | EUR 268 |
|
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor. |
|||
AR-A014418 |
|||
| A3184-S | ApexBio | Evaluation Sample | EUR 81 |
|
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor. |
|||
AR-C155858 |
|||
| A3185-10 | ApexBio | 10 mg | EUR 991 |
|
Description: AR-C155858 is a potent and selective inhibitor of monocarboxylate transporters MCT1 and MCT2 with Ki values of 2.3nM and less than 10 nM, respectively [1].MCT is a monocarboxylate transporter family with 14 members. |
|||
AR-C155858 |
|||
| A3185-5 | ApexBio | 5 mg | EUR 611 |
|
Description: AR-C155858 is a potent and selective inhibitor of monocarboxylate transporters MCT1 and MCT2 with Ki values of 2.3nM and less than 10 nM, respectively [1].MCT is a monocarboxylate transporter family with 14 members. |
|||
AR-C155858 |
|||
| A3185-50 | ApexBio | 50 mg | EUR 2800 |
|
Description: AR-C155858 is a potent and selective inhibitor of monocarboxylate transporters MCT1 and MCT2 with Ki values of 2.3nM and less than 10 nM, respectively [1].MCT is a monocarboxylate transporter family with 14 members. |
|||
AR Antibody |
|||
| ABD6783 | Lifescience Market | 100 ug | EUR 438 |
AR Antibody |
|||
| DF6783 | Affbiotech | 200ul | EUR 304 |
|
Description: AR Antibody detects endogenous levels of total AR. |
|||
AR Antibody |
|||
| BF0418 | Affbiotech | 200ul | EUR 376 |
|
Description: AR antibody detects endogenous levels of total AR. |
|||
AR antibody |
|||
| 10R-2031 | Fitzgerald | 100 ul | EUR 403 |
|
Description: Mouse monoclonal AR antibody |
|||
AR antibody |
|||
| 70R-35838 | Fitzgerald | 100 ug | EUR 327 |
|
Description: Rabbit polyclonal AR antibody |
|||
pCDNA3.1-AR |
|||
| PVT18102 | Lifescience Market | 2 ug | EUR 300 |
Clematichinenoside AR |
|||
| TBW00371 | ChemNorm | 10mg | EUR 847 |
ar-Tumerone |
|||
| TBW01373 | ChemNorm | 5mg | Ask for price |
AR-C155858 |
|||
| B2743-1 | Biovision | 1 mg | EUR 348 |
AR Antibody |
|||
| AF6927 | Affbiotech | 100ul | EUR 350 |
KAF/AR/ Rat KAF/ AR ELISA Kit |
|||
| ELA-E0006r | Lifescience Market | 96 Tests | EUR 886 |
Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
| 4-RPC623Hu01 | Cloud-Clone |
|
|
|
Description: Recombinant Human Molybdenum Cofactor Synthesis 1 expressed in: E.coli |
|||
Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
| 4-RPC623Mu01 | Cloud-Clone |
|
|
|
Description: Recombinant Mouse Molybdenum Cofactor Synthesis 1 expressed in: E.coli |
|||
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx131326 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx131327 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx113871 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx321401 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx321402 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx321947 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx322547 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx304514 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx036894-100ug | Abbexa | 100 ug | EUR 391 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx037731-100ug | Abbexa | 100 ug | EUR 391 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx135733 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx005887 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx025653-400ul | Abbexa | 400 ul | EUR 523 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx025653-80l | Abbexa | 80 µl | EUR 286 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx028710-400ul | Abbexa | 400 ul | EUR 523 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx028710-80l | Abbexa | 80 µl | EUR 286 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx235264-100ug | Abbexa | 100 ug | EUR 481 |
AR-C102222 (hydrochloride) |
|||
| HY-12122A | MedChemExpress | 10mg | EUR 1175 |
AR Polyclonal Antibody |
|||
| ES4268-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against AR from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES4268-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against AR from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5938-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against AR from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5938-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against AR from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5939-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against AR from Human. This antibody is tested and validated for IHC, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5939-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against AR from Human. This antibody is tested and validated for IHC, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5940-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against AR from Human/Mouse. This antibody is tested and validated for IHC, IF, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5940-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against AR from Human/Mouse. This antibody is tested and validated for IHC, IF, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5941-100ul | ELK Biotech | 100ul | EUR 279 |
|
Description: A Rabbit Polyclonal antibody against AR from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
AR Polyclonal Antibody |
|||
| ES5941-50ul | ELK Biotech | 50ul | EUR 207 |
|
Description: A Rabbit Polyclonal antibody against AR from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
Anti-AR antibody |
|||
| STJ118653 | St John's Laboratory | 100 µl | EUR 277 |
Anti-AR Antibody |
|||
| STJ193178 | St John's Laboratory | 200 µl | EUR 197 |
Anti-AR antibody |
|||
| STJ22662 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract from the normal 9-34 repeats to the pathogenic 38-62 repeats causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Two alternatively spliced variants encoding distinct isoforms have been described. |
|||
AR ELISA Kit |
|||
| STJ150094 | St John's Laboratory | 1 kit | EUR 412 |
|
Description: The kit is a competitive enzyme immunoassay for in vitro quantitative measurement of T in serum, plasma and other biological fluids |
|||
Anti-AR antibody |
|||
| STJ114876 | St John's Laboratory | 100 µl | EUR 277 |
|
Description: The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract from the normal 9-34 repeats to the pathogenic 38-62 repeats causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Two alternatively spliced variants encoding distinct isoforms have been described. |
|||
AR Polyclonal Antibody |
|||
| ABP53269-003ml | Abbkine | 0.03ml | EUR 158 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse, Rat. This AR antibody is for WB, IF, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human AR |
|||
AR Polyclonal Antibody |
|||
| ABP53269-01ml | Abbkine | 0.1ml | EUR 289 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse, Rat. This AR antibody is for WB, IF, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human AR |
|||
AR Polyclonal Antibody |
|||
| ABP53269-02ml | Abbkine | 0.2ml | EUR 414 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse, Rat. This AR antibody is for WB, IF, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human AR |
|||
AR Polyclonal Antibody |
|||
| ABP54939-003ml | Abbkine | 0.03ml | EUR 158 |
|
Description: A polyclonal antibody for detection of AR from Human. This AR antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S650 |
|||
AR Polyclonal Antibody |
|||
| ABP54939-01ml | Abbkine | 0.1ml | EUR 289 |
|
Description: A polyclonal antibody for detection of AR from Human. This AR antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S650 |
|||
AR Polyclonal Antibody |
|||
| ABP54939-02ml | Abbkine | 0.2ml | EUR 414 |
|
Description: A polyclonal antibody for detection of AR from Human. This AR antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S650 |
|||
AR Polyclonal Antibody |
|||
| ABP54940-003ml | Abbkine | 0.03ml | EUR 158 |
|
Description: A polyclonal antibody for detection of AR from Human. This AR antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S213 |
|||
AR Polyclonal Antibody |
|||
| ABP54940-01ml | Abbkine | 0.1ml | EUR 289 |
|
Description: A polyclonal antibody for detection of AR from Human. This AR antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S213 |
|||
AR Polyclonal Antibody |
|||
| ABP54940-02ml | Abbkine | 0.2ml | EUR 414 |
|
Description: A polyclonal antibody for detection of AR from Human. This AR antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S213 |
|||
AR Polyclonal Antibody |
|||
| ABP54941-003ml | Abbkine | 0.03ml | EUR 158 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse. This AR antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S94 |
|||
AR Polyclonal Antibody |
|||
| ABP54941-01ml | Abbkine | 0.1ml | EUR 289 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse. This AR antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S94 |
|||
AR Polyclonal Antibody |
|||
| ABP54941-02ml | Abbkine | 0.2ml | EUR 414 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse. This AR antibody is for IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of S94 |
|||
AR Polyclonal Antibody |
|||
| ABP54942-003ml | Abbkine | 0.03ml | EUR 158 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse, Rat. This AR antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of Y363 |
|||
AR Polyclonal Antibody |
|||
| ABP54942-01ml | Abbkine | 0.1ml | EUR 289 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse, Rat. This AR antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of Y363 |
|||
AR Polyclonal Antibody |
|||
| ABP54942-02ml | Abbkine | 0.2ml | EUR 414 |
|
Description: A polyclonal antibody for detection of AR from Human, Mouse, Rat. This AR antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human AR around the non-phosphorylation site of Y363 |
|||
AR-42J cells |
|||
| C0018004 | Addexbio | One Frozen vial | EUR 455 |
AR (pS213) Antibody |
|||
| 20-abx000354 | Abbexa |
|
|
AR (pS650) Antibody |
|||
| 20-abx000355 | Abbexa |
|
|
Anti-AR antibody |
|||
| STJ97233 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: AR is a protein encoded by the AR gene which is approximately 99,1 kDa. AR is localised to the nucleus and cytoplasm. It is involved in deubiquitination, gene expression, metabolism of proteins and the nuclear receptor transcription pathway. It functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. AR is expressed in the liver, nervous system, blood, muscle and kidney. Mutations in the AR gene may result in prostate cancer. STJ97233 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of AR protein. |
|||
Anti-AR antibody |
|||
| STJ97845 | St John's Laboratory | 100 µl | EUR 234 |
|
Description: Mouse monoclonal to AR. |
|||
Anti-AR antibody |
|||
| STJ97846 | St John's Laboratory | 100 µl | EUR 234 |
|
Description: Mouse monoclonal to AR. |
|||
Anti-AR antibody |
|||
| STJ91659 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to AR. |
|||
Anti-AR antibody |
|||
| STJ91660 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to AR. |
|||
Anti-AR antibody |
|||
| STJ91661 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to AR. |
|||
Anti-AR antibody |
|||
| STJ91662 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to AR. |
|||
AR Conjugated Antibody |
|||
| C32572 | SAB | 100ul | EUR 397 |
AR Polyclonal Antibody |
|||
| 40609-100ul | SAB | 100ul | EUR 252 |
AR Polyclonal Antibody |
|||
| 40609-50ul | SAB | 50ul | EUR 187 |
AR Polyclonal Antibody |
|||
| 40610-100ul | SAB | 100ul | EUR 252 |
AR Polyclonal Antibody |
|||
| 40610-50ul | SAB | 50ul | EUR 187 |
AR-beta3 Antibody |
|||
| 44295-100ul | SAB | 100ul | EUR 252 |
AR-beta3 Antibody |
|||
| 44295-50ul | SAB | 50ul | EUR 187 |
AR Polyclonal Antibody |
|||
| 41904-100ul | SAB | 100ul | EUR 252 |
AR Polyclonal Antibody |
|||
| 41904-50ul | SAB | 50ul | EUR 187 |
Recombinant Human AR |
|||
| P0503 | FN Test | 100ug | EUR 522.36 |
|
Description: Recombinant Human protein for AR |
|||
AR-M 1896 |
|||
| B5328-1 | ApexBio | 1 mg | EUR 486 |
|
Description: Binding IC50: 1.76 nM for rGalR2; 879 nM for hGalR1Galanin is a 29-aa neuropeptide with a complex role in pain processing. Galanin receptor subtypes are present in dorsal root ganglia and spinal cord with a differential distribution. |
|||
AR-C 102222 |
|||
| B5504-10 | ApexBio | 10 mg | EUR 421 |
AR-C 102222 |
|||
| B5504-50 | ApexBio | 50 mg | EUR 1617 |
Netarsudil (AR-13324) |
|||
| B7807-2 | ApexBio | 2 mg | EUR 305 |
|
Description: Ki: 0.43141.3 nMNetarsudil (AR-13324) is a ROCK inhibitor.The Rho kinases are serine/threonine protein kinases existing as 2 isoforms, ROCK1 and ROCK2, which are widely expressed in various tissues, such as the trabecular meshwork. |
|||
Netarsudil (AR-13324) |
|||
| B7807-5 | ApexBio | 5 mg | EUR 444 |
|
Description: Ki: 0.43141.3 nMNetarsudil (AR-13324) is a ROCK inhibitor.The Rho kinases are serine/threonine protein kinases existing as 2 isoforms, ROCK1 and ROCK2, which are widely expressed in various tissues, such as the trabecular meshwork. |
|||
AR Blocking Peptide |
|||
| DF6783-BP | Affbiotech | 1mg | EUR 195 |
AR-beta3 Antibody |
|||
| AF9021 | Affbiotech | 200ul | EUR 304 |
|
Description: AR-beta3 Antibody detects endogenous levels of total AR-beta3. |
|||
AR Blocking Peptide |
|||
| BF0418-BP | Affbiotech | 1mg | EUR 195 |
anti-AR (1A9D12) |
|||
| LF-MA30225 | Abfrontier | 100 ul | EUR 486 |
|
Description: Mouse Monoclonal to AR |
|||
AR- beta3 Antibody |
|||
| ABF9021 | Lifescience Market | 100 ug | EUR 438 |
Beta3-AR Antibody |
|||
| 3939-200 | Biovision | EUR 354 | |
Beta3-AR Antibody |
|||
| 3939-30T | Biovision | EUR 146 | |
Bovine MOCOS/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E0183Bo | Sunlong | 1 Kit | EUR 717 |
Mouse Mocos/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E0967Mo | Sunlong | 1 Kit | EUR 632 |
Human MOCOS/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E1626Hu | Sunlong | 1 Kit | EUR 605 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (HRP) |
|||
| 20-abx304515 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (FITC) |
|||
| 20-abx304516 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (Biotin) |
|||
| 20-abx304517 | Abbexa |
|
|
Human Molybdenum Cofactor Synthesis 1 (MOCS1) Protein |
|||
| 20-abx650079 | Abbexa |
|
|
In conclusion, ATO can be effectively encapsulated into liposomes by remote loading method via Cu(OAc)2 gradients; the co-administration of ATO and Cu(II) via liposomal formulation may find wide applications in the treatment of various tumors.
